The Concept of Guillain–Barré Syndrome (GBS) in Unani Medicine and the Potential Role of Unani Pharmacology in Its Management

Year : 2025 | Volume : 14 | Issue : 02 | Page : 32 52
    By

    Sana Kauser Ateeque Ahmed,

  • Yezam Akhtar,

  • Patel Mohd Furqan Ahmad,

  1. Assistant Professor, Department of Mahiyatul Amraz (Pathology), Mohammadia Tibbia College & Assayer Hospital, Malegaon, Maharashtra, India
  2. Assistant Professor, Department of Tahaffuzi wa samaji Tib (Community Medicine), Mohammadia Tibbia College & Assayer Hospital, Malegaon, Maharashtra, India
  3. Assistant Professor, Department of Moalijat, Mohammadia Tibbiya College and Assayer Hospital, Malegaon, District Nashik, Maharashtra, India

Abstract

Introduction: Guillain–Barré Syndrome (GBS) is an autoimmune neurological disorder characterized by progressive muscle weakness and paralysis due to immune-mediated damage to the peripheral nervous system. Conventional treatments focus on immunotherapy and supportive care, but alternative approaches, such as Unani Medicine offer promising holistic management strategies. Unani Medicine attributes GBS to humoral imbalance, particularly an excess of Balgham (Phlegm) affecting nerve function, leading to weakness and dysfunction. Objective: This study aims to explore the concept of GBS in Unani Medicine and evaluate the potential role of Unani pharmacology, including single and compound drugs, antioxidants, and neuroprotective agents, in its management. Methodology: A literature survey of classical Unani texts was conducted to identify single and compound Unani formulations relevant to GBS management. Electronic databases, such as PubMed, ScienceDirect, Wiley Online Library, and Google Scholar were explored to collect scientific evidence on the effectiveness of the recommended Unani medicines for GBS treatment. Additionally, an extensive review of both classical Unani literature and modern research was conducted to analyze the connection between Unani concepts of nerve disorders and their possible role in GBS management. Conclusion: Unani Medicine offers a holistic and personalized approach to GBS management through herbal therapies. However, additional clinical studies and trials are required to confirm its effectiveness and safety. Integrating Unani pharmacology with modern medical research can provide novel adjunctive therapies for GBS, improving patient outcomes in a comprehensive manner

Keywords: Guillain-Barré Syndrome; neurological disorder; Unani medicine; Amraz asab

[This article belongs to Journal of AYUSH: Ayurveda, Yoga, Unani, Siddha and Homeopathy ]

How to cite this article:
Sana Kauser Ateeque Ahmed, Yezam Akhtar, Patel Mohd Furqan Ahmad. The Concept of Guillain–Barré Syndrome (GBS) in Unani Medicine and the Potential Role of Unani Pharmacology in Its Management. Journal of AYUSH: Ayurveda, Yoga, Unani, Siddha and Homeopathy. 2025; 14(02):32-52.
How to cite this URL:
Sana Kauser Ateeque Ahmed, Yezam Akhtar, Patel Mohd Furqan Ahmad. The Concept of Guillain–Barré Syndrome (GBS) in Unani Medicine and the Potential Role of Unani Pharmacology in Its Management. Journal of AYUSH: Ayurveda, Yoga, Unani, Siddha and Homeopathy. 2025; 14(02):32-52. Available from: https://journals.stmjournals.com/joayush/article=2025/view=208197


References

  1. Alagappan R. Manual of Practical Medicine. 1st ed. New Delhi: Jaypee Brothers Medical Publishers; 2013.
  2. Sheikh KA. Guillain-Barré syndrome. Continuum (Minneap Minn). 2020 Oct 1;26(5):1184–204.
  3. Aragonès JM, Altimiras J, et al. Incidence and clinical characteristics of Guillain-Barré syndrome in Osona (Barcelona, Spain), 2003–2016. Neurología (Engl Ed). 2021 Sep 1;36(7):525–30.
  4. Davidson’s Principles and Practice of Medicine. 23rd ed. Philadelphia, PA: Elsevier; 2018. p. 995.
  5. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 21st ed. Vol. 2. New York: McGraw Hill; 2022. p. 2462.
  6. Upte S. The Short Textbook of Pediatrics. 14th ed. New Delhi: Jaypee Brothers Medical Publishers; 2021.
  7. Feasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AF, Koopman WF. The pathological basis of conduction block in human neuropathies: a short-term experimental study. Brain. 1986;109(5):789–803.
  8. Chiba A, Kusunoki S, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology. 1993;43(10):1911–7.
  9. McKhann GM, Cornblath DR, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993;33(4):333–42.
  10. Uncini A, Kuwabara S. The electrodiagnosis of Guillain-Barré syndrome subtypes: where do we stand? Clin Neurophysiol. 2018;129(12):2586–93.
  11. Al-Din AN, Anderson M. Acute sensory neuropathy: a variant of Guillain-Barré syndrome? J Neurol Neurosurg Psychiatry. 1991;54(9):768–71.
  12. Young RR, Asbury AK, et al. Pure pandysautonomia with recovery: description and differentiation from acute autonomic neuropathy. Brain. 1975;98(4):613–36.
  13. Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol. 1986;43(11):1150–2.
  14. Asbury AK, Cornblath DR, Feasby TE. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27(S1):S21–4.
  15. Usaiba IA. Uyunulanba fi Tabqatil Atibba. Vol. II. New Delhi: CCRUM; 1990. p. 28, 69.
  16. Al-Qitfi JA. Tarikh-al-Hukama. New Delhi: CCRUM; 2012. p. 378, 544.
  17. Majoosi A. Kamil-us-Sana’a. New Delhi: Idara Kitab-us-Shifa; 2010.
  18. Nafis B. Kulliyat-e-Nafisi. New Delhi: Idara Kitab-us-Shifa; 1954.
  19. Rushd I. Kitab-ul-Kulliyat. New Delhi: CCRUM; 1987.
  20. Sina I. Alqanoon-Fit-Tib. New Delhi: Idara Kitab-us-Shifa; YNM.
  21. Arzani A. Tibb-e-Akbar. Deoband: Faisal Publications; 1890. p. 73.
  22. Jurjani I. Zakhira Khwarizam Shahi. New Delhi: Idara Kitab-us-Shifa; 2010. p. 76.
  23. Tabari AH. Moalajat Al-Buqratiyah. Vol. 1. New Delhi: CCRUM; 1995–97.
  24. Standard Unani Medical Terminology. New Delhi: CCRUM; 2012.
  25. Rushd I. Kitab-ul-Kulliyat. New Delhi: CCRUM; 1987.
  26. Jurjani I. Zakhira Khwarizam Shahi. New Delhi: Idara Kitab-us-Shifa; 2010.
  27. Majoosi A. Kamil-us-Sana’a. New Delhi: Idara Kitab-us-Shifa; 2010.
  28. Tabari AH. Moalajat Al-Buqratiyah. Vol. 1. New Delhi: CCRUM; 1995–97.
  29. Ṭabari R. Firdaus-ul-Hikmat-Fit-Tibb. New Delhi: CCRUM; 2010.
  30. Jurjani I. Zakhira Khwarizam Shahi. New Delhi: Idara Kitab-us-Shifa; 2010.
  31. Zuhr I. Kitab-ul-Taiseer Fil-Madavat-e-Wa-al-Tadbeer. 1st ed. New Delhi: CCRUM; 1986.
  32. Government of India. The Unani Pharmacopeia of India. Vol. I–VI. New Delhi: Ministry of AYUSH; 2007.
  33. Khan A. Muhit-i-Azam. New Delhi: Central Council for Research in Unani Medicine; 2012.
  34. Ghani N. Khazainul Advia. New Delhi: Idara Kitabusshifa; 2015.
  35. Said HM. Hamdard Pharmacopoeia of Eastern Medicine. South Asia Books; 1970.
  36. National Formulary of Unani Medicines (NFUM). New Delhi: CCRUM, Ministry of Health and Family Welfare; 2005.
  37. Ministry of AYUSH, Government of India. National List of Essential AYUSH Medicines. New Delhi; 2022.
  38. Lee J, Meijer E, Langa KM, et al. Prevalence of dementia in India: national and state estimates from a nationwide study. Alzheimers Dement. 2023;19(7):2898–912. doi:10.1002/alz.12928.
  39. Khan HN, Xia ZK, Perveen N. Phytochemical analysis, antibacterial and antioxidant activity determination of Ocimum sanctum. Pharm Pharmacol Int J. 2018;6(6). doi:10.15406/ppij.2018.06.00223.
  40. Chawla A, Kaur R, Sharma AK. Ficus carica: A review on its pharmacognostic, phytochemical and pharmacological aspects. Int J Pharm Pharmacol Res. 2012;1(4):215–32.
  41. Haider S, et al. [Article in Nutrición Hospitalaria]. Nutr Hosp. 2012;27(6):2109–15. doi:10.3305/nh.2012.27.6.6140.
  42. Badhe S, Badhe R, et al. Evaluations of antidepressant activity of Anacyclus pyrethrum root extract. Int J Green Pharm. 2010;4(2):79. doi:10.4103/0973-8258.63880.
  43. Chaurasia S. Anti-inflammatory and antioxidant activity of Strychnos nux vomica Am Eurasian J Sustain Agric. 2009;3(2):244–52.
  44. Kalam M. AZARAQI (Strychnos Nuxvomica): A novel drug of Unani system of medicine for the management of nerve and phlegmatic diseases. World J Pharm Life Sci. 2020;6:100–6.
  45. Kumari K, Adhikari P, Pandey A, Samant SS, Lal M, Pande V. Influence of solvent polarity on phytochemicals, antioxidants, and antimicrobial properties of Delphinium denudatum: A medicinal herb from Sainj Valley, Himachal Pradesh, India. Bioactivities. 2024;2(1):30–40.
  46. Nag G, De B. Acetylcholinesterase inhibitory activity of Terminalia chebula, Terminalia bellerica, and Emblica officinalis and some phenolic compounds. Int J Pharm Pharm Sci. 2011;3(3):121–4.
  47. Patil AD, Patil AY, Raje AA. Antidepressant-like property of Hyoscyamus niger in mouse model of depression. Innov Pharm Pharmacol. 2013;1(2):60–9.
  48. Güneş E, Uysal A, Aktümsek A, Durak Y. Hyoscyamus Reticulatus’un hekzan ve su özütlerinin antioksidan ve antimikrobiyal özellikleri üzerine. Selçuk Univ J Sci. 2014;(39):21–9.
  49. Azhar M, Mustehasan. Phytopharmacology of an important Unani drug Bazr-ul-Banj (Hyoscyamus niger) – Review. Asian J Pharm Clin Res. 2020;(Aug):28–32. doi:10.22159/ajpcr.2020.v13i9.38166.
  50. Pushkar GK, Pushkar BK, Sivabalan R. A review on major bioactivities of Bacopa monnieri. Adv Appl Biomed Sci. 2015;2(2):1–2.
  51. Goswami S, Saoji A, Kumar N, Thawani V, Tiwari M, Thawani M. Effect of Bacopa monnieri on cognitive functions in Alzheimer’s disease patients. Public Health. 2011;3(4).
  52. Liu J, Chen M, Wang X, et al. Piperine induces autophagy by enhancing protein phosphatase 2A activity in a rotenone-induced Parkinson’s disease model. Oncotarget. 2016;7(38):60823–43. doi:10.18632/oncotarget.11661.
  53. Siddiaque N, Ahmad S, Mujeeb M. Mechanism-based protective effect of Delphinium denudatum on cisplatin-induced nephrotoxicity. Published online 2014.
  54. Bulló M, et al. Effect of whole walnuts and walnut-skin extracts on oxidant status in mice. Nutrition. 2010;26(7–8):823–8. doi:10.1016/j.nut.2009.09.002.
  55. Ahmad H, Ahmad S, et al. Isolation, crystal structure determination and cholinesterase inhibitory potential of isotalatizidine hydrate from Delphinium denudatum. Pharm Biol. 2017;55(1):680–6. doi:10.1080/13880209.2016.1240207.
  56. Swathi G, Visweswari, et al. Evaluation of rotenone-induced Parkinson’s disease on glutamate metabolism and protective strategies of Bacopa monnieri. Int J Plant Anim Environ Sci. 2013;3:62–7.
  57. Bulló M, Nogués MR, et al. Effect of whole walnuts and walnut-skin extracts on oxidant status in mice. Nutrition. 2010;26(7–8):823–8. doi:10.1016/j.nut.2009.09.002.
  58. Muthaiyah B, et al. Dietary supplementation of walnuts improves memory deficits and learning skills in transgenic mouse model of Alzheimer’s disease. J Alzheimers Dis. 2014;42(4):1397–405. doi:10.3233/JAD–140675.
  59. Dhingra D, Sharma A. Antidepressant-like activity of n-hexane extract of nutmeg (Myristica fragrans) seeds in mice. J Med Food. 2006;9(1):84–9. doi:10.1089/jmf.2006.9.84.
  60. Mahato SB, Garai S, et al. Two jujubogenin bisdesmosides from Bacopa monniera. Phytochemistry. 2000;53(6):711–4. doi:10.1016/S0031-9422(99)00384-2.
  61. Zangiabadi N, Asadi-Shekaari M, Sheibani V, et al. Date fruit extract is a neuroprotective agent in diabetic peripheral neuropathy in streptozotocin-induced diabetic rats: A multimodal analysis. Oxid Med Cell Longev. 2011;2011:976948. doi:10.1155/2011/976948.
Regular Issue Subscription Review Article
Volume 14
Issue 02
Received 19/03/2025
Accepted 10/04/2025
Published 16/04/2025
Publication Time 28 Days
149

Login


My IP

PlumX Metrics